The listings featured on this site are from companies from which this site receives compensation. This influences where, how and in what order such listings appear on this site. Advertising Disclosure

Compare Semaglutide Weight Loss Injections 2026

Compare telehealth programs offering semaglutide with licensed clinician review — including what the trial data shows, what treatment really costs, and which program style fits you.

Last Updated: Jun 2026

What’s on this page?

  1. Top semaglutide programs of 2026 (above)
  2. What semaglutide is
  3. What the STEP 1 trial showed
  4. Which program type may fit you
  5. How semaglutide treatment works week to week
  6. Brand-name vs. compounded semaglutide
  7. Who should consider something else

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist — a prescription medication that acts on the hormone pathway controlling appetite, fullness, and blood sugar. For weight management, the FDA approved semaglutide 2.4 mg once weekly under the brand name Wegovy in June 2021, the first new drug approved for chronic weight management since 2014.

The approved indication covers adults with obesity (BMI 30 or higher), or overweight (BMI 27 or higher) with at least one weight-related condition, always in combination with a reduced-calorie diet and increased physical activity.

What did the STEP 1 trial show?

STEP 1 is the landmark trial behind semaglutide's weight-management approval. Among 1,961 adults without diabetes, those taking once-weekly semaglutide 2.4 mg with lifestyle intervention averaged a 14.9% reduction in body weight at week 68, compared with 2.4% in the placebo group.

The distribution matters as much as the average: 86.4% of semaglutide participants lost at least 5% of body weight, 69.1% lost at least 10%, and roughly half lost 15% or more. Nausea and diarrhea were the most common side effects — typically transient and mild-to-moderate, but the reason some participants discontinued.

Treat those numbers as a supervised-trial benchmark, not a promise. Your dose tolerance, adherence, and lifestyle changes will shape your own curve.

Which semaglutide program may fit you?

Telehealth programs package the same molecule very differently. Use the chart above to shortlist, then match the program type to your situation:

  • Insurance-first programs check your coverage for brand-name Wegovy before you pay anything — the right starting point if you have commercial insurance.
  • Cash-pay flat-price programs bundle the visit, medication, and shipping into one monthly number — easier to budget, but confirm what happens at dose increases.
  • Coaching-inclusive programs add nutrition and habit support, which mirrors how semaglutide was actually studied — alongside lifestyle intervention.

How does treatment work week to week?

Semaglutide for weight management is a once-weekly injection under the skin. Prescribers start at a low dose and step up gradually so your body can adjust — an approach designed to limit the gastrointestinal side effects seen in trials.

NIDDK guidance adds a useful checkpoint: if you have not lost at least 5% of your starting weight after 12 weeks on the full dose, your health care professional will likely reassess whether to continue, switch, or stop. Build that review into your expectations from day one.

Brand-name vs. compounded semaglutide

Some telehealth companies advertise compounded semaglutide at prices well below brand-name Wegovy. Compounded drugs are pharmacy-prepared versions that are not FDA-approved products, so the quality controls differ from the branded supply chain.

If a program offers compounded medication, ask three questions before paying: which pharmacy fills the prescription, what exactly is in the vial, and who monitors your treatment. A trustworthy program answers all three in plain language on its site.

Who should consider something else?

Semaglutide is not appropriate during pregnancy, while planning pregnancy, or while breastfeeding, per NIDDK guidance on weight-management medications. People with significant gastrointestinal conditions or a history of reactions to GLP-1 medications need an individual risk discussion with their clinician.

If weekly injections do not fit your life, oral prescription options and structured coaching programs exist — and for some people they are the better first step. The goal is sustained weight management, not a specific molecule.

Ready to compare semaglutide programs?

Pick two or three companies from the chart, read their full reviews, and verify the three-month cost, the pharmacy source, and the clinician access before you start an online visit.

Sources used for medical context

  1. FDA Wegovy approval bulletin (2021) for the semaglutide 2.4 mg indication.
  2. STEP 1 trial (NEJM, PMID 33567185) for weight-loss outcomes and side effects.
  3. NIDDK for eligibility, pregnancy guidance, and the 12-week response checkpoint.

How We Rank

Learn more about how comparetreatments.com rankings are determined.

Frequently Asked Questions (FAQ)

Semaglutide is the active ingredient; Wegovy is the brand approved by the FDA for chronic weight management at the 2.4 mg weekly dose. Other semaglutide brands carry different approved uses, which is why a licensed clinician decides which product fits your situation.
In the STEP 1 trial, the semaglutide 2.4 mg group averaged a 14.9% body-weight reduction at week 68 versus 2.4% for placebo, with 86.4% losing at least 5%. Real-world results vary with dose tolerance, adherence, and lifestyle support.
Yes. Semaglutide is prescription-only in the United States. Telehealth programs route you through an online intake reviewed by a licensed clinician, who can approve or decline treatment. Avoid any seller that skips medical review entirely.
Nausea and diarrhea were the most frequent side effects in the STEP 1 trial — usually transient and mild-to-moderate, though they led some participants to stop treatment. Gradual dose escalation exists partly to manage this. Tell your care team about persistent symptoms.
NIDDK guidance suggests reassessing if you have not lost at least 5% of your starting weight after 12 weeks on the full dose. At that point your clinician may adjust the dose, switch medications — tirzepatide is one alternative — or pivot to a different treatment plan entirely.